167 related articles for article (PubMed ID: 17729378)
1. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.
Davis RL; Rubanowice D; McPhillips H; Raebel MA; Andrade SE; Smith D; Yood MU; Platt R;
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1086-94. PubMed ID: 17729378
[TBL] [Abstract][Full Text] [Related]
2. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects.
Anderson KN; Lind JN; Simeone RM; Bobo WV; Mitchell AA; Riehle-Colarusso T; Polen KN; Reefhuis J
JAMA Psychiatry; 2020 Dec; 77(12):1246-1255. PubMed ID: 32777011
[TBL] [Abstract][Full Text] [Related]
3. Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: a meta-analysis of cohort studies.
Zhang TN; Gao SY; Shen ZQ; Li D; Liu CX; Lv HC; Zhang Y; Gong TT; Xu X; Ji C; Wu QJ
Sci Rep; 2017 Feb; 7():43085. PubMed ID: 28220881
[TBL] [Abstract][Full Text] [Related]
4. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.
Shen ZQ; Gao SY; Li SX; Zhang TN; Liu CX; Lv HC; Zhang Y; Gong TT; Xu X; Ji C; Wu QJ; Li D
Br J Clin Pharmacol; 2017 Apr; 83(4):909-922. PubMed ID: 27770542
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Selective Serotonin Reuptake Inhibitor Use Among Pregnant Women From 2017 to 2020 in King Abdulaziz Medical City, Jeddah, Saudi Arabia: A Retrospective Study.
Hakami AY; Ahmad RG; Bukhari MM; Almalki MA; Ahmed MM; Alghamdi MM; Kalantan MA; Alsulami KM
Cureus; 2023 Oct; 15(10):e47745. PubMed ID: 38021702
[TBL] [Abstract][Full Text] [Related]
6. Prenatal antidepressant use and risk of congenital malformations: A population-based cohort study.
Chan JKN; Lee KCK; Wong CSM; Chang WC
Psychiatry Res; 2024 Jun; 339():116038. PubMed ID: 38889560
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Antidepressants in Pregnancy.
Yue M; Kus L; Katta S; Su I; Li L; Haas DM; Quinney SK
J Clin Pharmacol; 2023 Jun; 63 Suppl 1(Suppl 1):S137-S158. PubMed ID: 37317494
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of pre-delivery taper in pregnant women taking antidepressants.
Robakis TK; Miyares S; Bergink V
Acta Psychiatr Scand; 2023 Jul; ():. PubMed ID: 37421329
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant use in pregnancy and the risk of cardiac defects.
Huybrechts KF; Palmsten K; Avorn J; Cohen LS; Holmes LB; Franklin JM; Mogun H; Levin R; Kowal M; Setoguchi S; Hernández-Díaz S
N Engl J Med; 2014 Jun; 370(25):2397-407. PubMed ID: 24941178
[TBL] [Abstract][Full Text] [Related]
10. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.
Reis M; Källén B
Psychol Med; 2010 Oct; 40(10):1723-33. PubMed ID: 20047705
[TBL] [Abstract][Full Text] [Related]
11. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy.
Colvin L; Slack-Smith L; Stanley FJ; Bower C
Birth Defects Res A Clin Mol Teratol; 2011 Mar; 91(3):142-52. PubMed ID: 21381184
[TBL] [Abstract][Full Text] [Related]
12. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study.
Ban L; Gibson JE; West J; Fiaschi L; Sokal R; Smeeth L; Doyle P; Hubbard RB; Tata LJ
BJOG; 2014 Nov; 121(12):1471-81. PubMed ID: 24612301
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study.
Nordeng H; van Gelder MM; Spigset O; Koren G; Einarson A; Eberhard-Gran M
J Clin Psychopharmacol; 2012 Apr; 32(2):186-94. PubMed ID: 22367660
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine in the first trimester and the prevalence of congenital malformations.
Cole JA; Ephross SA; Cosmatos IS; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1075-85. PubMed ID: 17729379
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant use during early pregnancy and the risk of congenital anomalies.
Vasilakis-Scaramozza C; Aschengrau A; Cabral H; Jick SS
Pharmacotherapy; 2013 Jul; 33(7):693-700. PubMed ID: 23744675
[TBL] [Abstract][Full Text] [Related]
16. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD.
Margulis AV; Abou-Ali A; Strazzeri MM; Ding Y; Kuyateh F; Frimpong EY; Levenson MS; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):942-51. PubMed ID: 23733623
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy.
Einarson A; Pistelli A; DeSantis M; Malm H; Paulus WD; Panchaud A; Kennedy D; Einarson TR; Koren G
Am J Psychiatry; 2008 Jun; 165(6):749-52. PubMed ID: 18381907
[TBL] [Abstract][Full Text] [Related]
18. Delivery outcome in relation to maternal use of some recently introduced antidepressants.
Lennestål R; Källén B
J Clin Psychopharmacol; 2007 Dec; 27(6):607-13. PubMed ID: 18004128
[TBL] [Abstract][Full Text] [Related]
19. Sertraline use during pregnancy and the risk of major malformations.
Bérard A; Zhao JP; Sheehy O
Am J Obstet Gynecol; 2015 Jun; 212(6):795.e1-795.e12. PubMed ID: 25637841
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
